12:00 AM
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Indoximod: Phase II started

NewLink Genetics said the University of Minnesota began a double-blind, placebo-controlled Phase II trial to evaluate twice-daily oral indoximod for 6 months starting after the last infusion of Provenge sipuleucel-T...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >